Full-Time

Data Analyst

Reporting Partnerships

Doximity

Doximity

501-1,000 employees

Professional networking, residency tools, telehealth

Compensation Overview

$77k - $134k/yr

+ Equity

Remote in USA + 1 more

More locations: San Francisco, CA, USA

Remote

Remote within the United States; SF office optional.

Category
Data & Analytics (1)
Required Skills
Python
SQL
Business Analytics
Data Analysis

Get referred to Doximity

See people who can refer or advise you

Requirements
  • At least 2 years of professional experience working in business analytics or performance reporting.
  • Excellent SQL skills to create and evaluate complex statements involving numerous tables and data relationships.
  • Fluency in Python, with hands-on experience building, maintaining, and debugging scripts for data processing or reporting.
  • Experience stepping into client-facing roles, especially to translate technical solutions for non-technical audiences.
  • Strong organizational skills and attention to detail; ability to stay ahead of multiple deadlines at once.
  • A proactive, ownership-oriented mindset: comfortable working through scripting updates largely on your own, escalating questions or issues when necessary.
  • A continuous-improvement focus, always looking to automate operational processes, elevate code quality, and deliver faster, more accurate reporting while strengthening value to clients.
Responsibilities
  • Generate and maintain Python-based client reporting used to power client measurement.
  • Deliver new Python scripts for reporting use cases, from adapting existing client templates to building custom client scripts end-to-end.
  • Conduct daily QA and act as a point-of-contact for teammates’ SQL and Python questions, helping raise the overall bar for code quality and consistency.
  • Create and maintain both Python and SQL-based aggregate reports as needed.

Doximity is a digital platform for United States healthcare professionals, offering a professional social network, a residency navigator, and telehealth services. Users join to connect with peers, share medical insights, track residency applications, and conduct remote patient visits. Revenue comes from targeted advertising to medical professionals, premium subscriptions, and telehealth usage fees. Its goal is to improve communication and collaboration among clinicians, support career development and residency placement, and expand access to care through convenient telehealth.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2010

Get referred to Doximity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 fiscal 2027 revenue rose 7.3% to $156.6 million, beating estimates.
  • Management raised full-year revenue guidance to $671 million-$681 million on AI traction.
  • CEO Jeffrey Tangney said AI Search earns over 10 times its running cost.

What critics are saying

  • Doximity settled a $31 million securities case on June 11, 2026.
  • Wells Fargo cut Doximity to Underweight after its 32.58% post-earnings jump.
  • OpenEvidence and Vera Health pressure Doximity by offering free clinician AI search.

What makes Doximity unique

  • Doximity reaches over 80% of U.S. physicians, giving unmatched clinician distribution.
  • Its late-April 2026 AI Search targets pharma budgets with physician-intent signals.
  • The Christ Hospital Health Network integrated Doximity Ask on April 7, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Family Planning Benefits

Paid Vacation

Paid Holidays

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Aug 18th, 2026
Doximity director sells 7,500 shares as stock jumps 33% after earnings beat

Timothy Cabral, a director at Doximity, sold 7,500 shares of Class A Common Stock on 7 August through a pre-arranged Rule 10b5-1 trading plan adopted in February. The sale occurred the day after Doximity's stock jumped 33% following earnings, though the timing was automatic rather than discretionary. The transaction reduced Cabral's direct holdings to 3,221 shares, but he retains 326,000 derivative securities. Doximity reported revenue of $156.6 million for the quarter, up 7%, whilst free cash flow fell 34% to $39.6 million. The company attributed the decline to accounts receivable timing. Doximity operates a cloud-based platform for healthcare practitioners and generates revenue through subscriptions from pharmaceutical companies and healthcare organisations. The stock had declined 50% over the prior year before the recent surge.

Yahoo Finance
Aug 18th, 2026
Doximity CAO sells $140K in shares via tax-related insider transaction

Doximity's Chief Accounting Officer Siddharth Sitaram disposed of 5,652 shares for $140,400 on 13 and 15 August, according to an SEC Form 4 filing. The transaction was non-discretionary and tax-related. It consisted of 3,882 shares withheld by the issuer to cover restricted stock unit vesting and 1,770 shares sold under a Rule 10b5-1 plan to satisfy tax obligations from an option exercise. Following the transaction, Sitaram maintains direct ownership of 93,122 shares and holds 59,000 derivative securities, with a post-transaction value of $2.31 million. Doximity operates a cloud-hosted digital platform for healthcare practitioners. The company reported trailing 12-month revenue of $655.6 million and net income of $167.0 million, with a market capitalisation of $4.6 billion.

Yahoo Finance
Aug 12th, 2026
Dutch Bros eyed as cash-producing coffee chain expanding rapidly with 27.7% growth forecast

Dutch Bros, the US coffee chain, is attracting attention for its strong same-store sales performance and expansion strategy. The company has achieved average same-store sales growth of 6% over the past two years and expects revenue growth of 27.7% for the next year. Meanwhile, two cash-generating companies face challenges. Doximity, the physician networking platform, has seen costs rise faster than revenue, with operating margins declining by 10.5 percentage points. Its estimated sales growth of 4.6% for the next 12 months suggests slowing demand. Silgan Holdings, the packaging supplier, has experienced annual revenue growth of just 4.7% over five years and earnings per share growth of only 2.4% annually.

Yahoo Finance
Aug 11th, 2026
Doximity's Q2 revenue rises 7.3% to $156.6M as AI adoption surges among clinicians

Doximity reported Q2 revenue of $156.6 million, up 7.3% year on year and beating analyst estimates of $151.3 million. The medical professional network's adjusted earnings per share of $0.29 missed expectations by 4.2%. The company attributed growth to increased adoption of AI-powered clinical tools. CEO Jeffrey Tangney noted quarterly active workflow prescribers grew more than 30% year on year, with nearly half using AI tools. Operating margin declined to 21.5% from 37.4% in the prior year period. The company raised full-year revenue guidance to $676 million from $670 million but set EBITDA guidance below analyst estimates at $319 million. CFO Matthew Sonefeldt said higher AI usage prompted increased investment to capture long-term opportunities, explaining near-term margin pressure.

Yahoo Finance
Aug 10th, 2026
Wells Fargo downgrades Doximity to underweight with $18 target after 33% post-earnings pop

Wells Fargo downgraded Doximity to Underweight from Equal Weight with an $18 price target, days after the medical professionals' digital platform surged 32.58% on earnings. Analyst Stan Berenshteyn noted that whilst Doximity's outlook remains unchanged, the stock now trades near faster-growing peers at approximately 32 times earnings despite roughly 11% revenue growth over the past year. The analyst argued remaining upside depends on an AI narrative that is difficult to quantify in estimates. Survey work suggests wallet-share gains with top accounts are largely complete. The $18 target sits at the bottom of analyst estimates ranging to $47. Wells Fargo cited unfavourable risk-reward until Doximity's AI strategy produces clearer growth acceleration.